

**Unaudited Financial Statements and Dividend Announcement
For the First Half and Six Months Ended 30 November 2020**

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3) AND FULL YEAR RESULTS

1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year

	Group		Change %
	30 November 2020 (Unaudited) S\$'000	30 November 2019 (Unaudited) S\$'000	
Revenue	10,980	9,769	12.4%
Other items of income			
Other income	702	461	52.3%
Fair value gain/(loss) on financial assets at FVTPL	1,542	(601)	N.M.
Items of expense			
Changes in inventories	(111)	64	N.M.
Inventories, consumables and surgery expenses	(1,312)	(1,122)	16.9%
Employee benefits expenses	(3,774)	(3,326)	13.5%
Depreciation and amortisation expenses	(734)	(564)	30.1%
Operating lease expenses	41	(156)	N.M.
Other expenses	(1,324)	(1,230)	7.6%
Finance costs	(100)	(121)	-17.4%
Profit before income tax	5,910	3,174	86.2%
Income tax expense	(649)	(599)	8.3%
Profit for the financial period, representing total comprehensive income for the financial period	5,261	2,575	104.3%
Profit and total comprehensive income attributable to:			
Owners of the parent	5,000	2,166	130.8%
Non-controlling interests	261	409	-36.2%
	5,261	2,575	104.3%

N.M. – Not meaningful

1(a)(ii) Notes to Consolidated Statement of Comprehensive Income

Profit for the financial period/year is stated after charging/(crediting) the following:	Half Year Ended	
	30 November 2020 (Unaudited) S\$'000	30 November 2019 (Unaudited) S\$'000
Allowance for impairment loss on doubtful third parties trade receivables written back	(2)	-
Amortisation of intangible assets	4	5
Depreciation of plant and equipment	219	190
Depreciation of right-of-use assets	511	369
Fair value (gain)/loss on financial assets at FVTPL	(1,542)	601
Gain on disposal of plant and equipment	-	(11)
Gain on lease modification	(1)	-
Loss on disposal of investments in subsidiaries	-	348

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

	Group		Company	
	30 November 2020 (Unaudited) S\$'000	31 May 2020 (Audited) S\$'000	30 November 2020 (Unaudited) S\$'000	31 May 2020 (Audited) S\$'000
ASSETS				
Non-current assets				
Plant and equipment	1,779	1,875	28	34
Intangible assets	4,789	4,062	6	8
Right-of-use assets	2,916	2,612	250	126
Investments in subsidiaries	-	-	5,993	5,261
Investment in associate	480	480	480	480
Investment in joint venture	90	90	90	90
Debt instruments at amortised cost	2,000	2,000	2,000	2,000
Financial assets at FVTPL	9,355	7,813	9,355	7,813
Deferred tax assets	12	12	-	-
Advance payments	-	15	-	15
Derivative financial instruments	1,921	1,921	2,463	2,463
Other receivables	579	564	804	876
	23,921	21,444	21,469	19,166
Current assets				
Inventories	359	470	-	-
Trade and other receivables	2,974	1,381	3,692	2,665
Prepayments	373	321	178	114
Cash and bank balances	7,960	6,788	3,209	4,347
	11,666	8,960	7,079	7,126
Total assets	35,587	30,404	28,548	26,292
EQUITY AND LIABILITIES				
Equity				
Share capital	15,419	15,419	15,419	15,419
Treasury shares	(652)	(541)	(652)	(541)
Merger reserve	(815)	(815)	-	-
Capital reserve	(3,930)	(3,773)	(164)	(7)
Other reserve	(1,928)	(1,928)	-	-
Retained earnings	11,862	7,919	5,765	3,775
Equity attributable to owners of the parent	19,956	16,281	20,368	18,646
Non-controlling interests	427	264	-	-
Total equity	20,383	16,545	20,368	18,646

	Group		Company	
	30 November 2020 (Unaudited) S\$'000	31 May 2020 (Audited) S\$'000	30 November 2020 (Unaudited) S\$'000	31 May 2020 (Audited) S\$'000
Non-current liabilities				
Deferred tax liabilities	88	95	-	-
Derivative financial instruments	28	28	258	258
Other financial liabilities	2,417	2,417	-	-
Bank borrowings	4,375	5,000	4,375	5,000
Provisions	107	85	21	21
Lease liabilities	1,895	1,848	346	353
	<u>8,910</u>	<u>9,473</u>	<u>5,000</u>	<u>5,632</u>
Current liabilities				
Trade and other payables	3,358	2,610	2,139	1,573
Bank borrowings	625	-	625	-
Provisions	15	37	-	-
Lease liabilities	1,105	880	304	257
Current income tax payable	1,191	859	112	184
	<u>6,294</u>	<u>4,386</u>	<u>3,180</u>	<u>2,014</u>
Total liabilities	<u>15,204</u>	<u>13,859</u>	<u>8,180</u>	<u>7,646</u>
Total equity and liabilities	<u>35,587</u>	<u>30,404</u>	<u>28,548</u>	<u>26,292</u>

1(b)(ii) Aggregate amount of group's borrowings and debt securities

Amount repayable in one year or less, or on demand

As at 30 November 2020 (Unaudited)		As at 31 May 2020 (Audited)	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	625	-	-

Amount repayable after one year

As at 30 November 2020 (Unaudited)		As at 31 May 2020 (Audited)	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
-	4,375	-	5,000

Details of collaterals

Not applicable.

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

Consolidated Statement of Cash Flows

	Half Year Ended	
	30 November 2020 (Unaudited) S\$'000	30 November 2019 (Unaudited) S\$'000
Operating activities		
Profit before income tax	5,910	3,174
Adjustments for:		
Allowance for impairment loss on doubtful third parties trade receivables written back	(2)	-
Amortisation of intangible assets	4	5
Depreciation of plant and equipment	219	190
Depreciation of right-of-use assets	511	369
Dividend income	(309)	(253)
Fair value (gain)/loss on financial assets at FVTPL	(1,542)	601
Gain on disposal of plant and equipment	-	(11)
Gain on lease modification	(1)	-
Interest income	(35)	(89)
Interest expense	100	121
Inventories written off	5	6
Loss on disposal of investments in subsidiaries	-	348
Plant and equipment written off	1	5
Operating cash flows before working capital changes	4,861	4,466
Working capital changes:		
Inventories	106	(39)
Trade and other receivables	(1,589)	(141)
Prepayments	(52)	(114)
Trade and other payables	772	(452)
Cash generated from operations	4,098	3,720
Income tax paid	(324)	(481)
Net cash from operating activities	3,774	3,239
Investing activities		
Acquisition of subsidiaries, net of cash acquired	(561)	-
Acquisition of additional equity interests in subsidiaries	-	(2,877)
Dividend received from a joint venture	15	-
Dividend received from financial assets at FVTPL	294	253
Interest received	20	75
Investment in an associate	-	(341)
Proceeds from disposal of plant and equipment	-	19
Purchase of plant and equipment	(164)	(864)
Net cash used in investing activities	(396)	(3,735)

	Half Year Ended	
	30 November 2020 (Unaudited) S\$'000	30 November 2019 (Unaudited) S\$'000
Financing activities		
Dividends paid to owners of the parent	(1,057)	(1,786)
Dividends paid to non-controlling interests	(98)	(472)
Interest paid	(99)	(7)
Proceeds from redeemable convertible loan	-	5,000
Purchase of treasury shares	(424)	-
Repayment of bank borrowings	-	(375)
Repayment of obligations under leases	(528)	(366)
Net cash (used in)/from financing activities	<u>(2,206)</u>	<u>1,994</u>
Net change in cash and cash equivalents	1,172	1,498
Cash and cash equivalents at beginning of financial period	<u>6,788</u>	<u>5,027</u>
Cash and cash equivalents at end of financial period	<u><u>7,960</u></u>	<u><u>6,525</u></u>

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

**Consolidated Statement of Changes in Equity
Group**

(Unaudited)

	Share capital	Treasury shares	Merger reserve	Capital reserve	Other reserve	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 June 2020	15,419	(541)	(815)	(3,773)	(1,928)	7,919	16,281	264	16,545
Profit for the financial period	-	-	-	-	-	5,000	5,000	261	5,261
Total comprehensive income for the financial period	-	-	-	-	-	5,000	5,000	261	5,261
Contributions by and distributions to owners									
Issue of shares	-	313	-	(157)	-	-	156	-	156
Purchase of treasury shares	-	(424)	-	-	-	-	(424)	-	(424)
Dividends	-	-	-	-	-	(1,057)	(1,057)	-	(1,057)
Total transactions with owners	-	(111)	-	(157)	-	(1,057)	(1,325)	-	(1,325)
Transactions with non-controlling interests									
Dividends	-	-	-	-	-	-	-	(98)	(98)
Total transactions with non-controlling interests	-	-	-	-	-	-	-	(98)	(98)
Balance at 30 November 2020	15,419	(652)	(815)	(3,930)	(1,928)	11,862	19,956	427	20,383

(Unaudited)

	Share capital	Treasury shares	Merger reserve	Capital reserve	Other reserve	Retained earnings	Equity attributable to owners of the Company	Non-controlling interests	Total equity
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 June 2019	14,433	(541)	(815)	(7)	(829)	7,631	19,872	410	20,282
Profit for the financial period	-	-	-	-	-	2,166	2,166	409	2,575
Total comprehensive income for the financial period	-	-	-	-	-	2,166	2,166	409	2,575
Contributions by and distributions to owners									
Issue of shares	986	-	-	-	-	-	986	-	986
Dividends	-	-	-	-	-	(1,786)	(1,786)	-	(1,786)
Total transactions with owners	986	-	-	-	-	(1,786)	(800)	-	(800)
Transactions with non-controlling interests									
Acquisition of non-controlling interests without a change in control	-	-	-	-	(3,818)	-	(3,818)	(46)	(3,864)
Disposal of non-controlling interests in a subsidiary	-	-	-	-	-	-	-	(19)	(19)
Dividends	-	-	-	-	-	-	-	(472)	(472)
Total transactions with non-controlling interests	-	-	-	-	(3,818)	-	(3,818)	(537)	(4,355)
Balance at 30 November 2019	15,419	(541)	(815)	(7)	(4,647)	8,011	17,420	282	17,702

**Statement of Changes in Equity
Company**

(Unaudited)	Share capital S\$'000	Treasury shares S\$'000	Capital reserve S\$'000	Retained earnings S\$'000	Total equity S\$'000
Balance at 1 June 2020	15,419	(541)	(7)	3,775	18,646
Profit for the financial period	-	-	-	3,047	3,047
Total comprehensive income for the financial period	-	-	-	3,047	3,047
Contributions by and distributions to owners					
Issue of shares	-	313	(157)	-	156
Purchase of treasury shares	-	(424)	-	-	(424)
Dividends	-	-	-	(1,057)	(1,057)
Total transactions with owners	-	(111)	(157)	(1,057)	(1,325)
Balance at 30 November 2020	15,419	(652)	(164)	5,765	20,368

(Unaudited)	Share capital S\$'000	Treasury shares S\$'000	Capital reserve S\$'000	Retained earnings S\$'000	Total equity S\$'000
Balance at 1 June 2019	14,433	(541)	(7)	6,804	20,689
Profit for the financial period	-	-	-	1,435	1,435
Total comprehensive income for the financial period	-	-	-	1,435	1,435
Contributions by and distributions to owners					
Issue of shares	986	-	-	-	986
Dividends	-	-	-	(1,786)	(1,786)
Total transactions with owners	986	-	-	(1,786)	(800)
Balance at 30 November 2019	15,419	(541)	(7)	6,453	21,324

- 1(d)(ii) Details of any changes in the company’s share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

Share Capital – Ordinary Shares

The Company’s issued and fully paid-up capital (excluding treasury shares) as at 30 November 2020 comprised 149,677,330 (31 May 2020: 150,565,730) ordinary shares. On 7 July 2020, the Company transferred 480,000 treasury shares to Dr. Goh Minghui as satisfaction of the consideration shares to be issued in connection with the acquisition of 51.0% of the entire issued share capital in GMH Endoscopy & Surgery Pte. Ltd. (“**GMHES**”). Subsequently in October and November 2020, the Company performed share buy-backs of 1,368,400 ordinary shares which were kept as treasury shares.

Outstanding Convertibles

The Company did not have any convertible instruments as at 30 November 2020 (30 November 2019: S\$5,000,000). The outstanding convertibles of S\$5,000,000 as at 30 November 2019 were in relation to the convertible bonds issued to Vanda 1 Investments Pte. Ltd. (“**Vanda 1**”) in August 2019.

Treasury Shares

There were 1,718,300 treasury shares (representing 1.15% of the Company’s 149,677,330 ordinary shares (excluding treasury shares)) as at 30 November 2020 and 829,900 treasury shares (representing 0.55% of the Company’s 150,565,730 ordinary shares (excluding treasury shares)) as at 30 November 2019.

Subsidiary Holdings

There were no subsidiary holdings as at 30 November 2020 and 30 November 2019.

- 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year**

	As at 30 November 2020	As at 31 May 2020
Total number of issued shares excluding treasury shares	149,677,330	150,565,730

- 1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on**

The Company had transferred 480,000 treasury shares during the half year ended 30 November 2020 to Dr. Goh Minghui as satisfaction of the consideration shares to be issued in connection with the acquisition of 51.0% of the entire issued share capital in GMHES. Subsequently in October and

November 2020, the Company also performed share buy-backs of 1,368,400 ordinary shares in aggregate which were kept as treasury shares.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on

Not applicable. There were no subsidiary holdings during and as at the end of the current financial period reported on.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice

The figures have not been audited or reviewed by the Company's auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter)

Not applicable. The figures have not been audited or reviewed by the Company's auditors.

3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:- (a) Updates on the efforts taken to resolve each outstanding audit issue, and (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed. This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

The accounting policies and methods of computation adopted in the financial statements for the reporting period are consistent with those disclosed in the most recently audited consolidated financial statements for the financial year ended 31 May 2020.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

There are no changes in the accounting policies and methods of computation for the current financial period reported on.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

Earnings per share ("EPS")	Group	
	Half Year Ended	
	30-Nov-20 (Unaudited)	30-Nov-19 (Unaudited)
Profit attributable to owners of the parent (S\$)	5,000,000	2,166,000
Weighted average number of ordinary shares in issue	150,644,943 ⁽¹⁾	149,296,222 ⁽²⁾
Basic EPS (cents per share)	3.32	1.45
Fully diluted EPS (cents per share) ⁽³⁾	3.32	0.21

Notes:-

- (1) The weighted average number of ordinary shares in issue for the half year ended 30 November 2020 was computed based on 150,565,730 ordinary shares as at 1 June 2020 and adjusted for (i) the transfer of 480,000 treasury shares to Dr. Goh Minghui on 7 July 2020 as satisfaction of the consideration shares for the acquisition of 51.0% of the equity interest in GMHES; and (ii) the buy-back of an aggregate of 1,368,400 shares which were kept as treasury shares in October and November 2020.
- (2) The weighted average number of ordinary shares in issue for the half year ended 30 November 2019 was computed based on 148,805,730 ordinary shares as at 1 June 2019 adjusted for the issue of 1,760,000 new ordinary shares to Dr. Julian Ong on 11 October 2019 as satisfaction of the consideration shares for the acquisition of an additional 19.0% of the equity interest in Julian Ong Endoscopy & Surgery Pte. Ltd ("JOES").
- (3) EPS on a fully diluted basis for the half year ended 30 November 2020 is the same as the basic EPS because the Company did not issue any potentially dilutive ordinary shares as at the end of the financial period. The fully diluted EPS as at 30 November 2019 was adjusted for the impact arising from the convertible bonds issued to Vanda 1.

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:

- (a) Current period reported on; and**
- (b) Immediately preceding financial year**

Net asset value ("NAV")	Group		Company	
	30-Nov-20 (Unaudited)	31-May-20 (Audited)	30-Nov-20 (Unaudited)	31-May-20 (Audited)
NAV (S\$)	19,956,000	16,281,000	20,368,000	18,646,000
Number of ordinary shares in issue	149,677,330	150,565,730	149,677,330	150,565,730
NAV per ordinary share (S\$ cents)	13.33	10.81	13.61	12.38

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss:-
- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
 - (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Review for the performance of the Group for the half year ended 30 November 2020 ("HY2021") as compared to the half year ended 30 November 2019 ("HY2020").

The increase in revenue of approximately S\$1.21 million was mainly due to the increase in the number of patients after the circuit breaker measures were lifted on 2 June 2020.

Other income increased by S\$241,000 due to higher government grants (including the Jobs Support Scheme) of S\$273,000 and higher dividend income from investment in financial assets at fair value through profit or loss ("FVTPL") of S\$41,000. This was partially offset by the decrease in interest income.

Fair value gain on financial assets at FVTPL of S\$1.54 million arose primarily due to (i) the increase in share price of Medinex Limited ("**Medinex**") in which the Company holds a direct interest of 22.92% and a deemed interest of 9.50% of the total issued share capital; and (ii) the increase in fair value of investment in Singapore Paincare Holdings Limited subsequent to its listing on the Catalist Board of the Singapore Exchange Securities Trading Limited on 30 July 2020 based on the quoted market share price. In HY2020, the fair value loss on financial assets at FVTPL of S\$0.60 million was due to the decrease in share price of Medinex.

Inventories, consumables and surgery expenses increased by S\$0.19 million in line with increased revenue.

Employee benefits expenses increased by approximately S\$0.45 million due to higher provision of bonus for the current financial year and increased headcount.

Operating lease expenses of negative S\$41,000 arose due to rental reliefs received during HY2021.

The increase in depreciation and amortisation expenses by S\$0.17 million was due to recognition of additional lease liabilities during the year for new and renewed tenancy agreements for clinic premises.

Finance costs decreased slightly by S\$21,000 mainly due to the redemption of the convertible bonds, issued to Vanda 1, in May 2020. This was partially offset by the increase in interest expenses for bank borrowings and lease liabilities.

As a result of the abovementioned, profit before income tax increased by approximately S\$2.74 million or 86.2% in HY2021 as compared to HY2020.

Income tax expense increased by S\$50,000 or 8.3% due to higher taxable profit recorded in HY2021 as compared to HY2020.

As a result of the abovementioned, profit after income tax increased by approximately S\$2.69 million or 104.3% in HY2021 as compared to HY2020.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

The comparative performance for both the assets and liabilities are based on the Group's financial statements as at 30 November 2020 and 31 May 2020.

Plant and equipment decreased from approximately S\$1.88 million as at 31 May 2020 to S\$1.78 million as at 30 November 2020 due to write off of plant and equipment for existing clinics partially offset by additions of plant and equipment for existing and new clinics.

Intangible assets comprise of goodwill and computer software. The increase in intangible assets from approximately S\$4.06 million as at 31 May 2020 to S\$4.79 million as at 30 November 2020 was primarily due to the increase in goodwill of approximately S\$0.73 million from the acquisition of GMHES in July 2020.

Right-of-use (“**ROU**”) assets increased by approximately S\$0.30 million mainly due to recognition of ROU assets for the new clinic.

Financial assets at FVTPL increased mainly due to change in fair value of approximately S\$1.54 million.

Inventories decreased by approximately S\$0.11 million due to an increase in medication and consumables sold during the financial year, which is in line with the increase in revenue.

Trade and other receivables increased by approximately S\$1.59 million due to an increase in trade receivables outstanding from patients, in line with higher revenue.

Capital reserve decreased by approximately S\$0.16 million due to the acquisition of 51.0% equity interest in GMHES in July 2020.

Trade and other payables increased by approximately S\$0.75 million mainly due to increased trade payables in line with increased revenue; and higher provision of bonus for the current financial year.

Current lease liabilities increased by approximately S\$0.23 million due to the new lease entered for the new clinic.

CONSOLIDATED STATEMENT OF CASH FLOWS

Review for the performance of the Group for the half year ended 30 November 2020 ("HY2021") as compared to the half year ended 30 November 2019 ("HY2020").

The Group recorded net cash from operating activities of S\$3,774,000 in HY2021 as compared to net cash from operating activities of S\$3,239,000 in HY2020, due mainly to higher revenue.

Net cash used in investing activities in HY2021 was primarily related to the acquisition of 51.0% equity interest in GMHES of S\$561,000 and the purchase of plant and equipment for existing and new clinics of S\$164,000. This was partially offset by the dividends received of S\$309,000. The net cash used in investing activities in HY2020 was mainly related to the acquisition of additional equity interests in JOES and Medical Services @ Tampines Pte. Ltd. of S\$2,877,000 and the purchase of plant and equipment for new clinics of S\$864,000.

Net cash used in financing activities in HY2021 was mainly related to (i) the payment of FY2020 final dividends of S\$1,057,000 to shareholders; (ii) share buy-backs of S\$424,000; and (iii) repayments of obligations under leases of S\$528,000.

Overall, the Group recorded a net increase in cash and cash equivalents of S\$1,172,000 in HY2021, resulting in cash and cash equivalents of S\$7,960,000 as at 30 November 2020.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as no forecast or a prospect statement has been disclosed previously.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Although the Group has seen pent up demand for its services in HY2021 post circuit-breaker period, it is uncertain if this trend will continue. Nevertheless, the Group continues to explore opportunities to improve its financial position.

In HY2021, the Group entered into an agreement with Prudential Assurance Company Singapore (Pte) Limited to provide cashless and quality healthcare services to its eligible customers at the Group's endoscopy centres in central and heartlands of Singapore.

In December 2020, the Group obtained its medical licence from the Ministry of Health for its Toa Payoh specialist clinic, located in the Toa Payoh central area within the Toa Payoh town centre and directly linked to Toa Payoh MRT station and bus interchange. The Group believes that this will further widen its reach to the population in the heartlands.

With the COVID-19 situation still raging globally and the slowdown of the economic activity, both local and worldwide, the Group is mindful to keep its operations intact and will continue to strengthen its core competencies to serve the local population well.

11. Dividend

If a decision regarding dividend has been made: -

- (a) Whether an interim (final) dividend has been declared (recommended)

Yes.

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	1.7 cents per ordinary share (one tier tax exempt)
Tax Rate	Tax Exempt

- (b) Previous corresponding period (cents)

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	1.3 cents per ordinary share (one tier tax exempt)
Tax Rate	Tax Exempt

- (c) The date the dividend is payable.

The dividend will be paid on 2 February 2021.

- (d) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

Notice is hereby given that the Share Transfer Books and Register of Members of the Company will be closed at 5.00 p.m. on 21 January 2021 for the purpose of determining shareholders' entitlements to the interim dividends.

Duly completed registrable transfers received by the Company's Share Registrar, Tricor Singapore Pte Ltd, 80 Robinson Road #02-00, Singapore 068898, up to the close of business at 5.00 p.m. on 21 January 2021, will be registered to determine shareholders' entitlements to the interim dividend.

12. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

Not applicable.

13. If the group has obtained a general mandate from shareholders for interested person transactions (“IPT”), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate from shareholders for interested person transactions.

Name of Interested Person	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than \$100,000 and transactions conducted under shareholders’ mandate pursuant to Rule 920) (S\$’000)	Aggregate value of all interested person transactions conducted under shareholders’ mandate pursuant to Rule 920 (excluding transactions less than \$100,000) (S\$’000)
CH Investment Holdings Pte. Ltd. ⁽¹⁾	413	-
G 7 Investment Holdings Pte. Ltd. ⁽²⁾	180	-

Notes:-

- (1) Rental of a portion of the entire clinic space at Blk 190 Lorong 6 Toa Payoh #01-572 Singapore 310190 from CH Investment Holdings Pte. Ltd., which is 50% owned by Dr. Heah Sieu Min (“HSM”) and 50% owned by Dr. Chia Kok Hoong (“CKH”), the Executive Directors of the Company. Please refer to announcement made on 1 September 2020.
- (2) Rental of a portion of the entire clinic space at Blk 801 Tampines Avenue 4 #01-273 (2nd Floor) Singapore 520801 from G 7 Investment Holdings Pte. Ltd., which is 50% owned by HSM and 50% owned by CKH, the Executive Directors of the Company.

14. Negative Confirmation by the Board Pursuant to Rule 705(5) of the Catalist Listing Manual

The Board of Directors of the Company confirms that, to the best of their knowledge, nothing has come to their attention which may render the unaudited financial results for HY2021 to be false or misleading in any material aspect.

15. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has procured undertakings from all of its directors and executive officers in the required format.

BY ORDER OF THE BOARD

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer
13 January 2021

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the "Company") was incorporated on 1 September 2015 in Singapore and listed on Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies and general surgery services with a focus on colorectal procedures across a network of 18 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made; or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.